The rare disease space is often overlooked, but it may be the most important laboratory we have for the future of medicine. Jimmy sits down with Rob Freishtat, board member of the Foundation for mRNA Medicines, to talk about what is actually driving collaboration between academic institutions and industry, what a changing regulatory landscape means for sites, and why financial viability and patient access are not as opposed as people think. Tune in now.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from SCRS Talks
How Agentic AI Is Transforming Clinical Research Site Operations
Features of Study Feasibility Technology
K2 Medical Research and Populace Health on Winning in CNS
The Missing Voice in AI Drug Development
Get summaries like this every morning.
Free AI-powered recaps of SCRS Talks and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.